Adjuvant therapy for high-risk gastrointestinal stromal tumour: Considerations for optimal management

Drugs

Volumn 72, Issue 15, 2012, Pages 1953-1963

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjuvants; Gastrointestinal stromal tumours; Imatinib; Protein tyrosine kinase inhibitors; Risk management

Indexed keywords

IMATINIB; REGORAFENIB; SUNITINIB;

ANEMIA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SIZE; CANCER TISSUE; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH RISK PATIENT; HUMAN; KIT GENE; LEG EDEMA; LEUKOPENIA; MITOSIS; MUSCLE CRAMP; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PDGFRA GENE; PERIORBITAL EDEMA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867321793     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635590-000000000-00000     Document Type: Review

References (70)

1. Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 2011; 6 (8): e20294
2. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in western Sweden. Cancer 2005; 103 (4): 821-9 (Pubitemid 40216412)
3. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors: a population-based study. BMC Cancer 2007; 7 (Dec 20): 230
4. Joensuu H, Vehtari A, Riihimä ki J, et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis based on pooled population-based cohorts. Lancet Oncol 2012; 13 (3): 265-74
5. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006; 37 (12): 1527-35 (Pubitemid 44792229)
6. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31 (1): 113-20 (Pubitemid 46036910)
7. Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34 (10): 1480-91
8. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012 Sep; 29 (3): 1765-72
9. Woodall CE, Brock GN, Fan J, et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 2009; 144 (7): 670-8
10. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11 (12): 865-78
11. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299 (5607): 708-10 (Pubitemid 36159485)
12. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2003; 125 (3): 660-7 (Pubitemid 37070684)
13. Pacini S, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16 (1): 79-88 (Pubitemid 350284184)
14. Agram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47 (10): 853-9
15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-80 (Pubitemid 34879334)
16. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-34 (Pubitemid 39296599)
17. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26 (4): 620-5 (Pubitemid 351264357)
18. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24 (29): 4764-74 (Pubitemid 46630941)
19. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368 (9544): 1329-38 (Pubitemid 44528723)
20. Demetri GD, Reichardt P, Kang Y-K, et al. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial [abstract no. LBA10008]. J Clin Oncol 2012; 30 (suppl.)
21. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, doubleblind, placebo-controlled trial. Lancet 2009; 373 (9669): 1097-104
22. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307 (12): 1265-72
23. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33 (5): 459-65 (Pubitemid 34747864)
24. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39 (10): 1411-9
25. DeMatteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract no. 8]. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL)
26. Kanda T, Nishida T, Wada N, et al. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients. Int J Clin Oncol. Epub 2011 Nov 23
27. Kang B, Lee J, Ryu M, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol 2009; 27 Suppl.: E21515
28. Zhan WH. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. J Clin Oncol 2007; 25 Suppl.: 556s
29. Nilsson B, Sjö lund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96 (11): 1656-8 (Pubitemid 46847213)
30. Huang H, Liang H, Zhan Z-L, et al. Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy. Med Oncol 2012 Jun; 29 (2): 941-7
31. Jiang WZ, Guan GX, Lu HS, et al. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol 2011; 104 (7): 760-4
32. Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37 (10): 319-24
33. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. V. 2.2011 [online]. Available from URL: http://www.nccn.org/pro fessionals/physician-gls/[Accessed 2012 Apr 25]
34. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine-kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37 (1): 75-88
35. Zhan WH, Wang PZ, Shao YF, et al. Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9 (5): 383-7
36. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25 (9): 1107-13 (Pubitemid 46596763)
37. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12 (8): 908-16 (Pubitemid 44175142)
38. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISGAGITG study 62005. Eur J Cancer 2007; 43 (6): 974-8 (Pubitemid 46505099)
39. Perik PJ, Rikhof B, de Jong FA, et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008; 19 (2): 359-61 (Pubitemid 351201720)
40. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23 (2): 70-83 (Pubitemid 44692418)
41. Gold JS, Gö nen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10 (11): 1045-52
42. Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35 (11): 1646-56
43. Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37 (10): 890-6
44. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112 (3): 608-15 (Pubitemid 351186201)
45. Corless C, Ballman KV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28 Suppl.: 699s
46. Gal R, Rath-Wolfson L, Rosenblatt Y, et al. An improved technique for mitosis counting. Int J Surg Pathol 2005; 13 (2): 161-5 (Pubitemid 40617544)
47. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, andmolecular genetic study of 1765 cases with longterm follow-up. Am J Surg Pathol 2005; 29 (1): 52-68 (Pubitemid 40023952)
48. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term-followup. Am J Surg Pathol 2006; 30 (4): 477-89 (Pubitemid 43740149)
49. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 (23): 4342-9 (Pubitemid 46621810)
50. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30 (1): 90-6 (Pubitemid 43740214)
51. Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14 (14); 4550-5
52. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27 (19): 3141-7
53. Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28 (9): 1554-9
54. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 (8): 1093-103 (Pubitemid 44275331)
55. Bardsley MR, Horvá th VJ, Asuzu DT, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139 (3): 942-52
56. Reichardt P, Hartmann J, Sundby Hall K, et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment: the first analysis in the SSGXVIII/AIO trial patient population. Eur J Cancer 2011; 47 (2 Suppl.): 15
57. Von Mehren M. Follow-up results after 9 years of the ongoing, phase II B2222 trial of imatinib mesylate in patients with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol 2011; 29 Suppl.: 609s
58. Blesius A. Who are the long responders to imatinib in patients with advanced GIST? Results of the BRF14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol 2011; 29 Suppl.: 616s
59. Davies HE, Wathen CG, Gleeson FV. The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ 2011; 342: d947
60. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 2011; 129: 2533-42
61. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19 (4): 1074-80
62. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14 (1): 14-24 (Pubitemid 44954266)
63. McAuliffe JC, Hunt KK, Lazar JF, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16 (4): 910-9
64. Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 2009; 27 Suppl.: 548s
65. BlesiusA, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastaticGIST in the prospective BRF 14 trial. BMC Cancer 2011; 11: 72
66. Reichardt P, Blay JY, Boukovinas I, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. Epub 2012 Jul 25
67. Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig 2007; 27 (2): 85-93 (Pubitemid 46143283)
68. Blanke CD, Huse DM. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. J Med Econ 2010; 13 (4): 681-90
69. Dretzke J, Round J, Connock M, et al. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours. Health Technol Assess 2010; 14 (2 Suppl.): 63-70
70. Sanon M, Taylor DC, Parthan A, et al. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. J Med Econ. Epub 2012 Jul 4